If you have severe osteoporosis, you have probably heard that most bone drugs work by slowing breakdown rather than building new bone. That framing is mostly accurate, and it is exactly why teriparatide gets attention: it works in the other direction. But is it for everyone with low bone density? Almost certainly not. And is the osteosarcoma warning you may have read about still relevant? No — and understanding why matters. Teriparatide (sold as Forteo, now also available as the biosimilar Bonsity) is an FDA-approved prescription peptide for severe osteoporosis with strong fracture-prevention trial data and a well-characterized safety profile, but it carries a firm 24-month lifetime treatment limit and requires sequential follow-on therapy to preserve its gains.
Summary
Teriparatide is a synthetic version of the first 34 amino acids of human parathyroid hormone, injected daily under the skin to stimulate bone formation. It is approved for postmenopausal women, men, and people whose osteoporosis is caused by long-term steroid use. The pivotal trial cut new vertebral fractures by 65% compared with placebo.
- What it is: Recombinant PTH (1-34), the biologically active N-terminal fragment of parathyroid hormone, produced in bacteria using recombinant DNA technology.
- How it works: Daily subcutaneous injection of 20 micrograms produces an intermittent PTH pulse that shifts bone metabolism toward net formation — a fundamentally different mechanism from bisphosphonates or denosumab, which are antiresorptive.
- Who it is approved for: Postmenopausal women at high fracture risk; men with primary or hypogonadal osteoporosis; men and women with glucocorticoid-induced osteoporosis at high fracture risk.
- Duration cap: 24 months of cumulative lifetime use per the FDA label, even though the black box osteosarcoma warning that originally prompted that limit was removed in 2020.
- After stopping: Bone gains are largely lost within 12 months unless a bisphosphonate or other antiresorptive agent is started promptly after the course ends.
- Cost and access: Forteo carries a high list price exceeding $3,000 per month; biosimilar Bonsity (FDA-approved 2023) offers a lower-cost alternative; Medicare Part B does not cover it (Part D does under certain plans).
- Hard limit: Teriparatide is contraindicated in pregnancy, in people with pre-existing hypercalcemia, and in those with conditions that raise the baseline risk of bone tumors (Paget disease, prior skeletal radiation, unexplained elevated alkaline phosphatase).
What Teriparatide Is: Recombinant PTH (1-34)
Parathyroid hormone is an 84-amino-acid peptide secreted by the parathyroid glands when blood calcium falls. Teriparatide is not the whole molecule — it is a synthetic copy of the first 34 amino acids at the N-terminal end, which carries the full biological activity at the PTH/PTHrP receptor expressed on osteoblasts, the cells that build bone.
The central pharmacological insight is that PTH's effect on bone depends entirely on the pattern of exposure. Continuous high PTH levels — as in hyperparathyroidism — drive net bone loss by recruiting osteoclasts. Pulsatile, intermittent exposure, delivered through a daily injection that briefly raises PTH and then lets it fall, preferentially activates osteoblast proliferation and drives net bone formation. This is the anabolic window teriparatide exploits.
The recombinant peptide is produced in Escherichia coli and formulated in a prefilled multi-dose pen injector. Eli Lilly received FDA approval in November 2002 (NDA 021318). Bonsity (Alvogen), FDA-approved in 2023, provides a biosimilar alternative at the same 20-microgram dose.
Anabolic vs. Antiresorptive Osteoporosis Therapy
Bone is constantly being remodeled: osteoclasts dissolve older bone, and osteoblasts deposit new matrix. Osteoporosis develops when that balance tilts toward resorption, weakening the trabecular lattice and raising fracture risk.
Antiresorptive drugs slow the resorption side. Bisphosphonates (alendronate, risedronate, zoledronate) bind to bone mineral and impair osteoclasts. Denosumab (Prolia) blocks RANK ligand, the signal that recruits osteoclasts. Both classes protect existing bone but do not add new bone.
Anabolic drugs work on the formation side. Teriparatide is the original anabolic agent in this class; abaloparatide (Tymlos, 2017) uses the same PTH/PTHrP receptor; romosozumab (Evenity, 2019) blocks sclerostin and simultaneously reduces resorption. In someone with multiple vertebral fractures and very low BMD, an antiresorptive preserves a structure that is already badly damaged. An anabolic can rebuild some of it.
The sequence order matters. Starting with a bisphosphonate and then switching to teriparatide produces smaller BMD responses than starting teriparatide in a treatment-naive patient, likely because suppressed bone turnover blunts the anabolic signal. A review in Bone summarized the evidence: "Initiation with an osteoanabolic agent followed by an antiresorptive seems to be the optimal treatment sequence, at least in patients with severe osteoporosis" (PMID 31990595).
FDA-Approved Indications
The FDA has approved teriparatide for three distinct populations, all sharing the qualifier "high fracture risk." Teriparatide is not a first-line drug for mildly low bone density; it is reserved for people who have already fractured, who carry T-scores below -2.5, or who have failed first-line therapy.
Postmenopausal women with osteoporosis at high risk for fracture. The largest and most-studied group. Estrogen loss after menopause sharply accelerates resorption, and this is the population enrolled in the pivotal NDA trial.
Men with primary or hypogonadal osteoporosis. Osteoporosis in men is underdiagnosed; men account for roughly 30% of hip fractures globally and have higher post-fracture mortality than women. Testosterone deficiency is a recognized driver, and teriparatide carries explicit approval here.
Men and women with glucocorticoid-induced osteoporosis at high fracture risk. Long-term corticosteroids (prednisone, dexamethasone) directly suppress osteoblast function and raise fracture risk, often before DXA changes are obvious. Teriparatide showed superior vertebral fracture prevention versus alendronate in a head-to-head trial in this population (NCT00051558).
Absolute contraindications include Paget's disease of bone, prior external beam radiation to the skeleton, open growth plates in pediatric patients, and existing bone malignancies.
The Pivotal Trial: Neer et al. (2001, NEJM)
The trial that carried teriparatide through FDA approval was published in the New England Journal of Medicine in May 2001 (PMID 11346808). It enrolled 1,637 postmenopausal women who already had at least one prior vertebral fracture — a high-risk population chosen specifically to detect a fracture-reduction signal within a manageable trial duration.
Women were randomized to 20 micrograms or 40 micrograms of teriparatide daily by subcutaneous injection, or to placebo, for a median of 21 months.
At the 20-microgram dose (the approved regimen), new vertebral fractures occurred in 14% of placebo and 5% of teriparatide patients — a 65% relative risk reduction. Nonvertebral fragility fractures: 6% placebo versus 3% teriparatide, a 53% reduction. Lumbar spine BMD rose 9 percentage points above placebo; femoral neck BMD rose 3 to 6 points. Only one dose, 20 micrograms daily, appears on the U.S. label; the 40-microgram arm did not meaningfully improve efficacy and was not approved.
These numbers represent the kind of hard fracture-endpoint data that distinguishes teriparatide from unproven compounds. The trial enrolled people who had already fractured, so the benefit was demonstrated where it matters most.
The 24-Month Treatment Limit: What It Means Now
If you research teriparatide, you will encounter the 24-month lifetime treatment limit quickly. You may also encounter references to an osteosarcoma black box warning. Understanding the current state requires separating two things that were originally linked but are now distinct.
Where the warning came from. Rats given high doses of teriparatide (3 to 60 times the human dose on a mcg/kg basis) for nearly their entire lifespan developed osteosarcomas at elevated rates. The FDA required a boxed warning prohibiting use in patients with increased baseline bone-tumor risk and capping lifetime use at 2 years.
What happened in 2020. After 15 years of postmarketing surveillance, the evidence in humans did not support the rodent signal. The definitive study by Gilsenan et al. (2021, Journal of Bone and Mineral Research, PMID 32990990) tracked osteosarcoma incidence among teriparatide users from 2003 to 2016. Of the osteosarcoma cases identified in the surveillance period, only 3 had prior teriparatide exposure. The standardized incidence ratio was 0.72 (90% CI: 0.20 to 1.86), meaning teriparatide users developed osteosarcoma at a rate below what would be expected in the general population matched for age, not above it. A complementary study linked pharmacy records to cancer registries across four matched cohorts and reached the same conclusion (PMID 35318162).
Based on this evidence, the FDA in 2020 removed the osteosarcoma boxed warning from the teriparatide label. That is a meaningful regulatory action — the FDA does not remove boxed warnings casually. A 2022 review by Krege et al. in Bone (PMID 36111201) documented the decision-making process in detail.
What remains in place. The 24-month cumulative lifetime treatment limit was revised along with the warning, but a treatment duration limit is still part of the current label. The practical guidance has not changed dramatically for most patients: teriparatide is still prescribed as a finite course of up to 24 months, not as an indefinite therapy. The rationale now rests more on practical grounds (the BMD gains from the drug plateau around 18 to 24 months, and cost is substantial) than on osteosarcoma fear. Some clinicians note the revised label may allow more flexibility in discussion with patients about re-treatment in exceptional cases, but the default course of therapy remains one 24-month cycle per lifetime.
The actionable takeaway for patients: the osteosarcoma concern that may have been described to you, or that you have read about, no longer carries the same regulatory weight it did before 2020. The contraindications around pre-existing bone malignancy risk still apply, because those patients were never appropriate candidates regardless. But for a postmenopausal woman without those risk factors, the removed black box is genuinely reassuring.
Side Effects and Safety Monitoring
The most common adverse effects reported in the pivotal trial and in postmarketing experience are generally manageable.
Dizziness and orthostatic hypotension. Because PTH has vascular effects, teriparatide can cause a transient drop in blood pressure in some patients, typically in the first few hours after injection. The FDA label recommends patients sit or lie down if they feel light-headed after dosing and advises injecting in a setting where they can sit comfortably for the first few uses.
Nausea and leg cramps. Both occur at rates modestly above placebo and tend to diminish after the first several weeks.
Hypercalcemia. Teriparatide can raise serum calcium; mild, transient hypercalcemia occurs in roughly 11% of patients in trial data, most cases asymptomatic and resolving without dose adjustment. Serum calcium monitoring at baseline and periodically during therapy is routine. Patients already taking large doses of supplemental calcium should discuss their total calcium intake with their prescriber before starting.
Renal stones. Hypercalciuria can follow from elevated calcium handling. A prior history of kidney stones is not an absolute contraindication but warrants explicit discussion with the prescribing physician.
Pregnancy. Teriparatide is contraindicated in pregnancy based on theoretical fetal harm from PTH-pathway stimulation. In the typical patient population — postmenopausal women and older men — this is rarely a practical concern, but it is noted explicitly because it appears on the label.
The honest read on teriparatide's safety: the drug has been in clinical use for over 20 years, and the osteosarcoma concern that once dominated patient discussions has been resolved by surveillance data. The residual risks — orthostatic dizziness, transient hypercalcemia, nausea — are detectable with standard monitoring and manageable in most patients.
Sequential Therapy: Why You Cannot Just Stop
This section deserves more attention than it typically gets in teriparatide discussions.
When teriparatide is stopped without a follow-on therapy, the bone gains erode. The anabolic signal disappears and the underlying remodeling imbalance of osteoporosis reasserts itself. Within 12 months of stopping, a substantial fraction of the BMD gains at the lumbar spine and hip are lost. A 24-month course without a planned follow-on is not a complete treatment; it is the first half of a two-part sequence.
The follow-on with the best evidence is an antiresorptive agent. Zoledronic acid (once-yearly IV bisphosphonate) and alendronate (weekly oral bisphosphonate) are both used in practice. A 2025 study in JCEM (PMID 38605469) showed that bisphosphonates stabilized BMD effectively after sequential anabolic therapy. Denosumab is also used, but stopping denosumab carries its own discontinuation risks.
Prior bisphosphonate use blunts the teriparatide response modestly, because suppressed bone turnover slows the anabolic machinery from reinitializing. For the highest-fracture-risk patients starting treatment for the first time, leading with teriparatide rather than a bisphosphonate produces the best net skeletal outcome.
The actionable takeaway: plan the follow-on before you start the first injection. It is not optional. It is the second chapter of the same treatment.
Cost, Access, and the Bonsity Biosimilar
Forteo's list price exceeds $3,000 per month, putting a full 24-month course above $72,000 at undiscounted cost. Most patients access it through commercial insurance (prior authorization required, documenting high fracture risk and failure of first-line therapy), Eli Lilly's patient assistance program, or Medicare Part D. Medicare Part B does not cover teriparatide because it is self-administered, not physician-administered.
Bonsity (teriparatide injection, Alvogen), approved by the FDA in 2023 as a biosimilar, offers the same 20-microgram dose with the same mechanism and clinical profile. Biosimilars in injectable categories typically enter at 20 to 30% below reference-product list price, though net negotiated prices vary. If cost is a barrier, asking your pharmacist or insurance team specifically about Bonsity substitution is a practical first step.
FAQ
Is teriparatide the same as growth hormone or a growth hormone secretagogue?
No. Teriparatide is a parathyroid hormone fragment. It acts on the PTH/PTHrP receptor on bone cells. It has no growth hormone pathway activity and no anabolic steroid characteristics. The mechanism, target tissue, and clinical use are entirely distinct from growth hormone or compounds like MK-677.
Can I use teriparatide if I have been on a bisphosphonate for years?
Yes, but prior bisphosphonate use modestly blunts the BMD response, particularly at the hip. The fracture-reduction benefit appears to be preserved even in this sequence. Your physician may discuss a washout period depending on your specific history.
Does teriparatide work for men?
Yes. The FDA approval explicitly covers men with primary or hypogonadal osteoporosis. Clinical trial data by Orwoll et al. showed significant BMD increases at the lumbar spine and femoral neck and reduced new vertebral fracture risk in this population.
What if I cannot tolerate daily injections?
The prefilled pen injector is generally well-tolerated, but patients with needle aversion or dexterity limitations can discuss auto-injector devices or nursing assistance with their prescribing team. There is no oral or intranasal teriparatide approved in the United States.
Is the osteosarcoma risk still a real concern?
For appropriate candidates, no. The 2020 removal of the boxed warning followed 15 years of postmarketing data showing a standardized incidence ratio of 0.72 — below background population rates. The contraindications that remain (Paget's disease, prior skeletal radiation, unexplained elevated alkaline phosphatase) are still real, and those patients should not use teriparatide. For a postmenopausal woman or man without those conditions, osteosarcoma is not a meaningful part of the current risk-benefit calculation.
Conclusion
Teriparatide is not a drug for a mildly abnormal DXA scan. It is for people with severe osteoporosis — multiple vertebral fractures, very low BMD, or glucocorticoid-driven disease — where antiresorptive therapy alone may be insufficient. In that population, the evidence is strong: a 65% reduction in vertebral fractures over 21 months is a clinically meaningful result.
The framework for responsible use is clear: confirm eligibility with a physician who has reviewed your full bone history; understand the 24-month limit and that the osteosarcoma warning is gone; plan the follow-on bisphosphonate before the first injection; and obtain it only through a licensed pharmacy on a valid prescription. For context on where teriparatide sits in the broader approved-peptide landscape, see the FDA-approved peptides overview. If you are evaluating whether bone-building therapy fits your age group and risk profile, peptides for women over 40 and peptides for seniors over 50 offer relevant framing.
The information in this article is for educational purposes only and does not constitute medical advice, diagnosis, or a recommendation for any specific treatment. Teriparatide is a prescription drug available only through a licensed physician and dispensed by a licensed pharmacy. Decisions about starting, stopping, or adjusting any osteoporosis therapy — including teriparatide — must be made in consultation with a qualified healthcare provider who has reviewed your complete medical history, current medications, and diagnostic test results. Never start or stop a prescription drug based on information read online.
This article is for informational purposes and not medical advice. Peptides, especially those marketed for therapeutic use, can interact with medications and health conditions. Consult a licensed physician before starting any supplement, particularly if you are pregnant, nursing, taking prescription medications, or managing a chronic condition.
